Latest Strategy News

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.

SKS Technologies reported a remarkable doubling of profit in FY25, driven by strong organic growth and a strategic acquisition that positions it for rapid expansion in Australia's largest data centre market.

Renegade Exploration has identified the Myschka prospect in Canada’s Yukon as a promising Reduced Intrusion-Related Gold System, with plans underway for maiden drilling in 2026. High-grade silver, gold, and antimony samples reinforce its potential within the prolific Tombstone Gold Belt.

Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.

Ausmon Resources reports promising rare earth element assay results from its Jabuk Prospect in South Australia, revealing concentrations up to 1,452 ppm TREO. The company plans an extensive grid drilling program to further define this emerging mineralisation.

HITIQ Limited has launched its PROTEQT™ concussion management system in North America, securing exclusive Canadian distribution rights and initiating a dual-channel market strategy targeting hockey’s vast ecosystem.

ReadCloud Limited reported a robust FY25 with a 109% surge in underlying EBITDA, driven by strong growth in its Australian school businesses. The company’s FY26 outlook targets continued organic expansion and disciplined execution amid industry funding uncertainties.

Cyprium Metals has secured board approval to restart copper cathode production at its Nifty Copper Complex, targeting first output by mid-2026. The plan leverages existing heap leach resources and refurbishes key processing infrastructure to generate near-term cash flow.

Acorn Capital Investment Fund Limited (ACQ) reported a strong FY25 performance with a 15.1% net return and declared 5.5 cents per share in dividends, reinforcing its position in the Australian microcap sector.

ReadCloud Limited reported a 5% revenue increase to $12.9 million for FY25, alongside a 109% surge in underlying EBITDA to $0.76 million, narrowing its statutory loss by 59%. Strong growth in its VET-in-Schools segment and domestic eBooks sales underpinned this improved financial performance.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.

IPH Limited reported solid FY25 profit growth driven by Canadian acquisitions and a promising FY26 start despite challenges in Australia and New Zealand. CEO Andrew Blattman announced his retirement for late 2026, marking a pivotal leadership transition.